The Prognostic Value of Different Molecular Subtypes of Breast Cancer in Relation to Enhancer-of-Zeste Homologue 2 Expression

Journal Title: Journal of Clinical and Diagnostic Research - Year 2019, Vol 13, Issue 7

Abstract

ABSTRACT Introduction: The role of Enhancer-of-zeste homologue 2 (EZH2) in breast cancer invasion and progression may be attributed to EZH2-mediated epigenetic repression of tumour cells. Aim: The study aimed to assess the prognostic value of different luminal subtypes of breast cancer in association with EZH2 protein expression. Materials and Methods: A cross-sectional analytical research study on breast cancer women was performed. The four major molecular subtypes of breast cancer were defined, as follows: luminal A, luminal B, HER2-type, and Triple-Negative/Basal-like (TNBC). Log Rank (Mantel-Cox) test of equality of survival function was then performed to assess statistical significance between groups. The effects of variables on Overall Survival (OS) and Event Free Survival (EFS), was then assessed to give adjusted Hazard Ratios (HRs) with 95% Confidence intervals (CIs). Results: Samples were collected for women with breast cancers, with follow-up data collected over a 5-year period, with the age range of 34-75 years. TNBC subgroup was twice as likely to have high EZH2 expression compared with the luminal A subgroup (as the reference group) (OR=2.06; 95% CI=0.22 to19.09), and the luminal B subgroup had a 35% reduced likelihood (OR=0.66; 95% CI=0.26 to1.70). Cox’s Regression analysis showed that the hazard of mortality was about 3 times more in HER2 subtype breast cancers than in the luminal A subgroup (HR=3.16; 95% CI: 1.30-15.45, p<0.005), while the Log Rank (Mantel-Cox) test showed a statistically significant difference in OS by molecular subtype at all-time points (p≤0.05). Conclusion: The results provide some interesting insights, confirming the prognostic differences by molecular subtypes, in relation to EZH2 protein expression. However, there remains controversy about the prognostic value of different molecular subtypes.

Authors and Affiliations

Zohreh Sanaat, Ashraf Fakhrjou, Faris Farassati, Roya Dolatkhah

Keywords

Related Articles

From Potpourri to Percipience: Developing Problem Solving Skills in Medical Students through a Computer Assisted Active Learning Strategy

ABSTRACT Introduction: Problem solving skills are of utmost importance to medical students who in the future would depend on them for diagnosing a case. However, there are very few avenues to develop problem solving skil...

A Morphological and Morphometric Study on Meniscofemoral Ligaments of Knee Joint and its Variations

ABSTRACT Introduction: There are two Meniscofemoral Ligaments (MFLs) in the knee joint, anterior Meniscofemoral Ligament (aMFL) and posterior Meniscofemoral Ligament (pMFL) named according to their position relative to P...

Clinical and Aetiological Profile of Neonates with Persistent Hypoglycaemia

ABSTRACT Disturbances of glucose homeostasis that result in hypoglycaemia is a common metabolic issue encountered in newborn. Most of the times, awareness of various risk factors that predispose infants to hypoglycaemia...

A Rare Case Report of Spindle Cell Ameloblastic Carcinoma Involving the Mandible

Ameloblastic Carcinoma (AC) is uncommon malignant epithelial odontogenic tumour of jaw, with characteristic histologic features and behavior. Clinically, it has aggressive, infiltrative growth pattern with a distinct pre...

Download PDF file
  • EP ID EP606684
  • DOI 10.7860/JCDR/2019/41610.13020
  • Views 107
  • Downloads 0

How To Cite

Zohreh Sanaat, Ashraf Fakhrjou, Faris Farassati, Roya Dolatkhah (2019). The Prognostic Value of Different Molecular Subtypes of Breast Cancer in Relation to Enhancer-of-Zeste Homologue 2 Expression. Journal of Clinical and Diagnostic Research, 13(7), 1-6. https://europub.co.uk/articles/-A-606684